Paper: Residual Monoclonal Free Light Chain Positivity By Mass Spectrometry Identifies Patients at Increased Risk of Early Relapse Following First-Line Anti-Myeloma Treatment

Oral and Poster Abstracts Oral 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Challenges in Multiple Myeloma Therapy: Adopting New Approaches for Relapse and Monitor Clinical Research, Technology and Procedures, Serologic Tests Hannah Victoria Giles, FRCPath, MRCP1*, Mark T Drayson, MD2*, Nicola Wright, MChem3*,…

Read the full article here

Source: ash.confex.com

Categories: Latest Headlines, Oncologists2

Tags: ASH21, massspec, MRD, myeloma

Tweets with this article

Martin Kaiser

Very much looking forward to first prospective evidence on #MRD guided therapy in #myeloma, e.g. from the MASTER trial at #ASH21 by @End_myeloma - as well exciting data on #MassSpec for MRD by Hannah Giles&Guy Pratt in NCRI Myeloma XI https://t.co/TfM55NXX1F https://t.co/ebIYQuQIJj

Paper: Phase III Study of Daratumumab/rhuph20 (nsc- 810307) + Lenalidomide or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapyin Patients with Multiple Myeloma (mm) Using Minimal Residual Disease Todirect Therapy Duration (DRAMMATIC study): SWOG s1803

Program: Oral and Poster Abstracts Session: 731. Clinical Autologous Transplantation: Results: Poster I Hematology Disease Topics & Pathways: Adult, Non-Biological, Therapies, Study Population, Clinically relevant…

Mike Thompson, MD, PhD, FASCO April 29, 2024

Job Advert

Skip to main content We’ ve put some small files called cookies on your device to help us make improvements to our site. To improve…

Martin Kaiser April 23, 2024

Paper: Global Access to Multiple Myeloma Medications (GLAMM-2 Study): Access and Barriers to Chemoimmunotherapies and Transplant

Program: Oral and Poster Abstracts Session: 652. Multiple Myeloma: Clinic al and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Clinical Practice (Health Services…